Chevron Left
Back to Drug Commercialization

Learner Reviews & Feedback for Drug Commercialization by University of California San Diego

4.7
stars
1,285 ratings

About the Course

The University of California San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences Drug Commercialization course brings you
lectures from both faculty and industry experts. With this course, recorded on campus at UCSD, we seek to share our access to top people in
the field who bring an unprecedented range of expertise on drug commercialization. This course will cover pharmacoeconomic, marketing
strategy, intellectual property strategy, portfolio management, managed markets and strategic alliances. It will also have a lecture case study
from startup to success. In addition, the course will discuss post-marketing clinical trials or Phase 4 trials. These are conduct...
...

Top reviews

JR

Jan 7, 2017

Excellent course on strategies for drug commercialization including pharmacoeconomics and how pharma partners with other stakeholders to accomplish this. Excellent examples of drug lifecycles.

AZ

Nov 9, 2020

Excellent content and lecturers. Great course to finish this specialization. I strongly recommend the three courses for those interested in pursuing a career in pharma or willing to shift.

Filter by:

226 - 245 of 245 Reviews for Drug Commercialization

By Mohamed T H

Jul 24, 2020

Much better than the Drug Discovery and Drug Development courses in this specialization. In particular, the 2nd half of 3rd week was understandable and clearly taught. That part I think was later added and was not a part of the lectures otherwise used in these courses. That section really showed the potential of these courses which unfortunately was not reached due to the lectures that were used. Most of the time the presentation slides were filled with so many texts that you would wonder if its a presentation or an article. This course was better than the previous two courses though. After completing the three courses I feel that these courses could be much better if the course providers would improve the presentations used. Nonetheless, the course was informative. But there's only so much that one can absorb with so busy slides with not so attractive layout.

By Dauletbekov

Jan 2, 2020

The course is exremely useful and packs a lot of knowledge, however it's regrettable that the course was made in 2013-2014, and since then it was not updated. The pauses at the beginning of videos make you unsure whether you hit the right button, so I think that videos could be better edited. I found that lectures with Remi Brouard were not focussed and sometimes repetitive with what Dr Ettouti said already on industry collaboration. Overall, I found the course extremely useful, providing lot of insightful knowledge.

By Kierstin L

Aug 23, 2017

Etouillie was great and his experience commentary made the course more interesting. His biosimilar section is highly pertinent to the US current situation with lawsuits flying every which way. I do wish more regulatory process steps were included. The start up success last section was not helpful. More just seemed like a quick review article one could read about an approved drug and the story of someone bragging about how lucky they were.

By Danna F M

Sep 29, 2019

The course was very interesting and cover differents topics to give me an overview of drug commercialization in USA. In addition, the experiences shared from the each professor was excelent. However, I didn't know that the majority of topics were made in 2013. So this information was missing when I applied for this course.

By George L

Mar 7, 2021

I found this course to be very engaging and informative about the Drug Development Process. However, most of the information is outdated - the course was recorded in 2015 and a lot has changed in pharma since then. I would give it a 5-stare rating if I had taken the course say 4-5 years ago.

By Dei M M L

Dec 26, 2021

It is an excellent course from Coursera for learning on strategies for drug commercialization including pharmacoeconomics and how pharmaceuticals partners with other stakeholders to accomplish this.

By Alexander B

Nov 2, 2020

Most of materials are quite outdated and also quality of presentations sometimes was not that good.

By Richik N M

Jul 19, 2020

Not enough materials on HEOR and Phase IV studies. Week 4's lectures were redundant.

By Saudamini R

Jun 8, 2020

Its a wonderful course, but i would request the faculty to include more recent data

By m_taisir k

Oct 24, 2017

some lectures are not understand

but generally

thank you

By Meg R

Jun 27, 2024

The managed markets data was old, needs to be updated.

By vincent l

Feb 19, 2018

It was alright, couldve given more examples and cases

By yousef e

Sep 29, 2019

i think part one in week 4 is too bad

By Deleted A

Jun 2, 2019

Audio ruim

By mark y

May 27, 2024

goodsir

By 普信男版Gary

Apr 17, 2024

So so

By Nisha k

Nov 3, 2022

good

By Hilal T

Sep 10, 2024

ok

By Deleted A

Sep 14, 2022

Outdated series of classes that offer no real learning opportunities.

By Se a

Jan 1, 2023

The course needs to be updated with much newer lectures.

The sound quality in a lot of the lectures was quite bad.